Par Drugs And Chemicals growth over the years

·UnclassifiedChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+2.7%+2.7%
EBITDA−12.2%−2.0%
Net Income−1.9%+5.0%
EPS (adj.)−1.9%+5.0%
Total Assets+8.2%+13.3%
Total Equity+13.2%+16.3%
Free Cash Flow−2.9%+36.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PAR₹120.70

Par Drugs And Chemicals Limited

· Unclassified
₹ CrorePeersBALAXICROWNSTEELCITYHINDCONLATTEYSHECPROJECTAIROLAMGROBTEAMcap ₹149 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+2.7+2.7
EBITDA-12.2-2.0
Net Income-1.9+5.0
EPS (adj.)-1.9+5.0
Total Assets+8.2+13.3
Total Equity+13.2+16.3
Free Cash Flow-2.9+36.1
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.